Lilly To Cease Development Of Alzheimer's Drug
Eli Lilly announced August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent.
You may also be interested in...
Some of the biggest life science VCs are spending hundreds of millions of dollars to run the clinical trials of drugs owned by big drugmakers. But if the strategy works, they may have come up with a better way to diversify their portfolios in an era when long-term company-building isn’t paying off.
Some of the biggest names in life science venture capital – OrbiMed Advisors, Clarus Ventures, and Abingworth – are spending hundreds of millions of dollars to run the clinical trials of drugs owned by Pfizer and other big drugmakers. They’re taking on major clinical and regulatory risks for what might be less-than-stellar returns but if it works, these VCs may have come up with a better way to diversify their portfolios in an era when long-term company-building isn’t paying off.
The Alzheimer’s Association International Conference is under way in Vancouver through July 19, but some of the most anticipated news regarding drug development for the disease is likely to take place later this year. There’s plenty of hope, but not much optimism that pivotal trials for bapneuzumab and solanezumab will succeed. Regardless of the outcome, the results will have an impact on which approaches to Alzheimer’s come next—and how they get funded.